News & Publications is here!

June 02, 2014 | Alexandra Mulvey

Yesterday, we launched a first-of-its-kind website devoted to cancer immunotherapy designed specifically for patients and their caregivers, (TheA2C). Through, Cancer Research Institute seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types. The site provides a robust but accessible overview of the science behind cancer immunotherapy, detailed information about cancer immunotherapy clinical trials, and voices from the cancer immunotherapy community.

Launched to coincide with the kickoff on June 1 of CRI’s second annual Cancer Immunotherapy Month, the new site includes “30 Days, 30 Stories: Surviving Cancer Through Immunotherapy” (also on the CRI website), powerful videos and written stories of patients, told in their own words, of their experiences with cancer immunotherapy. In some cases, they were not expecting to survive and, thanks to these new treatments, are now in remission.

Like the story of Pam Griffith, diagnosed with stage IV metastatic lung cancer, whose cancer was unresponsive to conventional therapy. In 2013, she enrolled in a clinical trial of an immunotherapy called nivolumab (BMS-936558), and within a month, her tumors melted away.

Or the story of Father Dennis Billy (online in two days), who enrolled in an immunotherapy clinical trial after a second recurrence of his acute lymphocytic leukemia. Using a technology called CAR T cell therapy, Father Billy’s doctors trained his own T cells (a key component of the immune system) to attack his cancer. Today, more than two years since treatment, he continues to be cancer free.

Building on the Cancer Research Institute’s more than 60-year commitment to advancing the science and understanding of cancer immunotherapy, the launch of represents the beginning of a new phase in CRI’s mission to conquer cancer through immunotherapy. is supported through a charitable donation from Bristol-Myers Squibb Company.
Blog post currently doesn't have any comments.